Cardiac Innovations Australia will promote sales of CardioComm Solutions’ Software into local Hospitals and Physician Based Institutions
TORONTO, ONTARIO – CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of electrocardiogram (“ECG”) acquisition and management software solutions, today announced that is has signed an agency agreement with Cardiac Innovations Australia Pty. Ltd. (“Cardiac Innovations”), a distributor of medical hardware and software solutions into local hospitals and clinics in Australia.
CardioComm Solutions acknowledged the Cardiac Innovations relationship once it was confirmed this distributor had successfully obtained an Australian Register of Therapeutic Goods Certificate from the Department of Health, Therapeutics Goods Administration (“TGA”). TGA clearance is the required regulatory approval for the sale of any of CardioComm Solutions’ products into the Australian medical market. The agreement with Cardiac Innovations also makes provision for the future sale of other CardioComm Solutions products and solutions with additional TGA clearances.
Cardiac Innovations sells into a diverse Australian customer base that includes cardiologists, hospitals, electrophysiologists and primary care physicians. Their initial focus with GEMS™ WIN will be on marketing into organizations active in cardiac device implantation and follow-up as well as supporting surveillance in the unexplained syncope and post-ablation patient population.
Cardiac Innovations’ interest to become an agent for distribution of the CardioComm Solutions products was in response to a number of Australian medical groups looking for access to the GEMS™ WIN technologies as an alternative, proven and well priced solution that would address their unmet performance and customer support needs. “While the market in Australia is quite diverse, it is currently dominated by one arrhythmia monitoring solution,” notes the Managing Director for Cardiac Innovations Australia. “Without local access to a complete cardiac monitoring solution which supports reporting, inventory tracking and varied patient ECG monitoring options, many Australian customers have looked outside the country by attending international conferences or have undertaken training in the United States and Canada through which they were exposed to the CardioComm Solutions’ portfolio of products. Other companies in Australia are unable to offer a complete and competitive product for the cardiac rhythm market and this is where the GEMS™ WIN arrhythmia monitoring solution will give us a significant and differentiated competitive advantage.”
CardioComm Solutions has reported that a global distribution channel is an important element of their ongoing sales expansion strategy. Securing a local agent to provide GEMS™ WIN sales, technical assistance and customer support in Australia is a competitive advantage for CardioComm Solutions and well positions Cardiac Innovations to realize strong market gains with future expansion potential across the Asia Pacific region.
